Continuous IOP monitor validated in initial trials

Implandata has announced that the first patients has been implanted with its EYEMATE continuous intraocular pressure (IOP) monitor and the technology passed initial validation. Glaucoma, as well as a few other less common eye conditions, require regular IOP measurements in order to properly adjust how much medications to take. Typically, this is done at the doctor’s office using a handheld tonometer, but such measurements are performed infrequently and vary significantly throughout even a single day.

The EYEMATE consists of an implant placed into the eye and a sensor that’s positioned in front of the eye every time a reading is to be taken. The patients can do this themselves, and in just about any setting. Readings take seconds to perform and medications adjusted quickly and according to the latest numbers.

The first implant, conducted at University Eye Hospital of Bochum, Germany, is part of a larger study to evaluate the device and to try out the smaller, 2.7 mm incision size that’s now required.

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Previous Post

Robotic mapping and navigation using TI's mmWave sensor

Next Post

Unbox and configure TI’s TPSM84205 power module EVM